We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins
News

Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins

Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins
News

Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novozymes and Prometic Enter Into Alliance for Purification of Albumin-Fusion Proteins"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novozymes and ProMetic Life Sciences Inc. have announced that they have entered into a strategic alliance regarding proprietary albumin purification technology based upon a synthetic-ligand affinity adsorbent developed by ProMetic’s UK subsidiary, ProMetic BioSciences Ltd. The purification technology has been designed for the rapid development of Novozymes’ albufuse® albumin-fusion molecules.

Under the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure®, as a platform approach for the purification of albumin and albumin-fusion proteins.

ProMetic will be the exclusive manufacturer and supplier of AlbuPure®, however both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure®.

ProMetic and Novozymes Biopharma, a subsidiary of Novozymes, have collaborated on the development of AlbuPure® which was derived from ProMetic’s Mimetic Ligand™ technology and targeted at the capture and purification of recombinant albumin proteins produced in yeast. AlbuPure® binds specifically to the albumin portion of the molecule and so can be used for the purification of any albufuse® albumin-fusion protein.
Advertisement